- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01835470
Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
February 24, 2021 updated by: Bristol-Myers Squibb
A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics
The purpose of this study is to assess the efficacy of Abatacept after intravenous administration in Japanese children and adolescents with active juvenile idiopathic arthritis who have a history of an inadequate response or intolerance to Methotrexate or biologics
Study Overview
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aichi
-
Oobu-shi, Aichi, Japan, 4748710
- Local Institution
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 0608648
- Local Institution
-
Sapporo-shi, Hokkaido, Japan, 0048618
- Local Institution
-
-
Hyogo
-
Kobe, Hyogo, Japan, 6500047
- Local Institution
-
-
Kagoshima
-
Kagoshima-shi, Kagoshima, Japan, 8908520
- Local Institution
-
-
Kanagawa
-
Yokohama-shi, Kanagawa, Japan, 2360004
- Local Institution
-
Yokohama-shi, Kanagawa, Japan, 2328555
- Local Institution
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan, 9893126
- Local Institution
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 9518520
- Local Institution
-
-
Okinawa
-
Nakagami-gun, Okinawa, Japan, 9030215
- Local Institution
-
-
Osaka
-
Takatsuki-shi, Osaka, Japan, 5698686
- Local Institution
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 1138603
- Local Institution
-
Shinjuku-ku, Tokyo, Japan, 1620054
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who have a history of an inadequate therapeutic response or intolerance in the opinion of the examining physician to at least one biologics or Methotrexate (MTX).
- Diagnosis of Juvenile Idiopathic Arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria as oligoarticular, polyarticular Rheumatoid Factor (RF+), polyarticular (RF-), or systemic with a polyarticular-course.
- Men and women, ages 4 to 17 years, inclusive at enrollment.
Subjects must have a history of at least 5 joints with active disease and must have currently active articular disease as defined by:
- ≥2 active joints (e.g. presence of swelling, or if no swelling is present, limitation of motion (LOM) accompanied by pain, tenderness, or both) at screening and at Week 0 (Day 1).
- ≥2 joints with LOM at screening and at Week 0 (Day 1).
Exclusion Criteria:
- Systemic onset JIA with any of the following manifestations within the last 6 months prior to enrollment: intermittent fever due to JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
- Presence of any other rheumatic disease or major chronic infectious/inflammatory/immunologic disease (e.g. inflammatory bowel disease, psoriatic arthritis, spondyloarthropathy, hypogammaglobulinemia, or systemic lupus erythematosus, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abatacept
Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16
Time Frame: Week 16 (Day 113)
|
American College of Rheumatology (ACR) pediatric (PED) 30 response was defined as '≥30% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables.
JIA core set variables defined as the number of active joints, number of joints with Limit of Motion (LOM), physician's global assessment of disease severity, patient global assessment of overall well being, parent assessment of physical function, and acute phase reactant value.
A non-responder imputation was applied.
|
Week 16 (Day 113)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing a American College of Rheumatology Pediatric 50, 70, 90 Response or Inactive Disease at Week 16
Time Frame: Week 16 (Day 113)
|
ACR PED 50 response is defined as '≥50% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables.
ACR PED 70 response is defined as '≥70% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables.
ACR PED 90 response is defined as '≥90% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables.
Inactive disease status is defined as no active joints, physician's global assessment of disease severity equal or less than 10mm and C-reactive protein (CRP) within normal limits (0.3 mg/dL).
A non-responder imputation is applied.
mm=millimeter; mg/dL=milligrams/deciliter
|
Week 16 (Day 113)
|
Median Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 16
Time Frame: Week 16 (Day 113)
|
Physical function was evaluated using the disability section of the Childhood Health Assessment Questionnaire (CHAQ).
The questionnaire was derived from the adult HAQ.
The disability section assessed physical functions in 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common activities.
The questions were evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 =unable to do.
Higher scores indicate greater dysfunction.
A disability index was calculated as the mean of the 8 functional scales.
The percentage of Improvement from baseline was calculated using the following equation: (Baseline value - Post-baseline value) / Baseline value x 100.
|
Week 16 (Day 113)
|
Number of Participants With Death, Serious Adverse Events (SAEs), Drug-Related SAEs, Discontinuation Due to Drug-Related SAEs, Drug-Related Adverse Events (AEs), and Discontinuation Due to Drug-Related AEs During the Short Term Period
Time Frame: Day 1 up to 56 days post Week 16 (Day 113); approximately 6 months
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
SAEs also include hospitalizations for elective surgical procedures.
Drug-related=related or missing relationship to study drug.
Data includes all events from the date of the first dose of the study drug up to 56 days post the last dose of the study drug in the short-term period or start of the long-term period, whichever occurred first.
|
Day 1 up to 56 days post Week 16 (Day 113); approximately 6 months
|
Maximum Observed Concentration (Cmax) of Abatacept During the Short Term Period
Time Frame: 9 time points up to Week 16 (Day 113)
|
Cmax was obtained from the serum concentration versus time data after intravenous administration of abatacept.
Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113.
A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110.
ug/mL=micrograms/milliliter
|
9 time points up to Week 16 (Day 113)
|
Trough Observed Concentration (Ctrough) of Abatacept During the Short Term Period
Time Frame: 9 time points up to Week 16 (Day 113)
|
Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113.
A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110.
ug/mL=micrograms/milliliter
|
9 time points up to Week 16 (Day 113)
|
Number of Participants With Positive Immunogenicity During the Short Term Period
Time Frame: Day 1 up to Week 16 (Day 113)
|
A positive immunogenicity response for 'Cytotoxic T-lymphocyte antigen (CTLA4), Immunoglobulin (Ig)', 'Ig and/or Junction Region', respectively = (1) missing baseline immunogenicity measurement and positive analytical laboratory reported immunogenicity response post-baseline (2) negative baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline (3) positive baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline with titer value strictly greater than the baseline titer value.
Assessment based on assay cutpoint value.
Serum samples were collected prior to study medication at Week 0 (Day 1), Week 8 (Day 57), and Week 16 (Day 113) in the short term period.
Participants who early discontinued from the study or complete and did not switch to commercial abatacept had a serum sample collected on final visit or early termination visit, 28, 84 and 168 days after the last dose.
|
Day 1 up to Week 16 (Day 113)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 9, 2013
Primary Completion (Actual)
November 24, 2015
Study Completion (Actual)
July 30, 2018
Study Registration Dates
First Submitted
April 17, 2013
First Submitted That Met QC Criteria
April 17, 2013
First Posted (Estimate)
April 19, 2013
Study Record Updates
Last Update Posted (Actual)
February 26, 2021
Last Update Submitted That Met QC Criteria
February 24, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Juvenile
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Immune Checkpoint Inhibitors
- Abatacept
Other Study ID Numbers
- IM101-365
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Idiopathic Arthritis
-
University of AarhusAarhus University HospitalCompletedPolyarticular Juvenile Rheumatoid Arthritis | Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis, OligoarthritisDenmark
-
Institut National de la Santé Et de la Recherche...CompletedSystemic-Onset Juvenile Idiopathic ArthritisFrance
-
GeneScience Pharmaceuticals Co., Ltd.Not yet recruitingActive Systemic Juvenile Idiopathic ArthritisChina
-
Novartis PharmaceuticalsCompletedSystemic Juvenile Idiopathic Arthritis (SJIA)Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic Arthritis With Active FlareUnited States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
-
University of British ColumbiaUniversity of Manitoba; The Hospital for Sick Children; McGill University Health... and other collaboratorsRecruiting
-
AbbVieCompletedPolyarticular Juvenile Idiopathic Arthritis
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile Idiopathic Arthritis (JIA)France
-
AbbVieRecruitingJuvenile Idiopathic Arthritis (JIA)United States, Germany, Hungary, Israel, Puerto Rico, Spain, Japan, Canada, Italy, Sweden
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedJuvenile Idiopathic Arthritis (JIA)United States
Clinical Trials on Abatacept
-
Bristol-Myers SquibbCompletedUlcerative ColitisUnited States, Australia, India, Korea, Republic of, Poland, Canada, France, Brazil, Mexico, Puerto Rico, Belgium, Switzerland, Italy, Netherlands, Germany, Ireland, South Africa, United Kingdom, Czech Republic
-
University Medical Center GroningenBristol-Myers SquibbCompletedSjögren's SyndromeNetherlands
-
Melbourne HealthNational Health and Medical Research Council, Australia; Juvenile Diabetes...Active, not recruitingDiabetes Mellitus, Type 1 | Type 1 DiabetesAustralia
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedMultiple Sclerosis, Relapsing-RemittingUnited States, Canada
-
Rüdiger B. MüllerBristol-Myers SquibbCompletedRheumatoid ArthritisSwitzerland
-
Karolinska InstitutetKing's College Hospital NHS Trust; Institute of Rheumatology, PragueCompletedDermatomyositis | PolymyositisSweden, Czechia
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted